Scotiabank Maintains Sector Outperform on Eli Lilly, Raises Price Target to $1605
Scotiabank analyst Louise Chen maintains Eli Lilly (NYSE:LLY) with a Sector Outperform and raises the price target from $1300 to $1605.
Share
Why It Matters
A bank analyst thinks Eli Lilly will do better than other drug companies. She raised her price guess, showing she believes the company is doing well.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.